Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin with Nivolumab and Ipilimumab in Relapsed SCLC
NCT04610658Phase 1Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Nov 2020
- Primary completion
- Mar 2023
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label trial of lurbinectedin in small cell lung cancer (SCLC) (3 arms), sponsored by Moffitt Cancer Center. Primary endpoints: Maximum Tolerated Dose up to 12 weeks and Disease Control Rate up to 12 months. Started Nov 2020; status: terminated.
02
Drugs
lurbinectedin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04610658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04610658.